53 results about "Calprotectin" patented technology

The invention provides an immuno-chromatography kit for quickly and quantitatively detecting calprotectin in excrement and belongs to the technical field of clinical in-vitro diagnosis reagents. The kit includes: a test strip, which includes a substrate, and a sample pad, a marker combination pad, a nitrocellulose membrane and a water absorption pad which are all arranged on the substrate. The marker combination pad is coated with a calprotectin monoclonal antibody A marked by colloidal gold particles, colloidal silver particles, colloidal iron particles, magnetic particles, fuel particles, latex particles or fluorescent particles. The nitrocellulose membrane contains a detection line T and a quality control line C, wherein the detection line T is formed by a calprotectin monoclonal antibody B, and the quality control line C is formed by goat-anti-mouse IgG. The calprotectin monoclonal antibody A and the calprotectin monoclonal antibody B respectively recognize different epitopes of the calprotectin. The kit is convenient and quick, is simple in operation, has accurate result and is suitable for clinical quick detection.

The invention discloses a calprotein detection kit as well as a preparation method and a detection method thereof. The kit comprises a box body and a piece of detection test paper arranged in the box body, wherein the detection test paper comprises a base plate as well as a sample pad, a first conjugate pad, a second conjugate pad, a coating membrane and a piece of water absorbing paper which are sequentially connected from left to right and are arranged on the base plate; the first conjugate pad contains a Eu<3+> latex microsphere-labeled anti-mouse calprotein antibody, and the second conjugate pad contains a biotinylated anti-mouse calprotein antibody; and a detection line T and a quality control line C which are in parallel arrangement are arranged on the coating membrane from left to right, the detection line T is coated with immobilized streptavidin, and the quality control line C is coated with an immobilized goat anti-mouse IgG antibody. The calprotein detection kit is convenient and efficient in detection, high in detection sensitivity, strong in specificity, high in repeatability, objective and reliable and can quantitatively detect calprotein.

The present invention concerns a method for determining the concentration of calprotectin in a sample. A lateral flow test kit and test element using said method are also provided.

The invention discloses a kit for detecting calprotectin in excrement. The kit comprises a PVC (Poly Vinyl Chloride) rubber plate, a nitrocellulose membrane, a water-absorbing pad, a colored particle/fluorescent particle compound pad, a sample pad, a detecting line and a quality control line, wherein the nitrocellulose membrane, the water-absorbing pad, the colored particle/fluorescent particle compound pad and the sample pad are arranged on the upper surface of the PVC rubber plate, and the detecting line and the quality control line are arranged on the upper surface of the nitrocellulose membrane. The kit for detecting calprotectin in excrement is used as a dynamic testing kit for domestic or medical institutions and is used for conveniently detecting the content of calprotectin in excrement; when the detecting sensitivity is 15mu g/g, the detecting time is only 3-5 minutes; the operation is simple; the performance is reliable; the cost is low; the sensitivity is high; the detecting time is short; the domestic and overseas blank is filled up.

Treatments are disclosed for inflammatory, autoimmune, or other disorders characterized by excessive activity of calprotectin, a protein that normally defends against microbial infections by sequestering available zinc, at a site of infection. Excessive calprotectin activity, which can cause zinc deficiencies in localized tissues, can create or aggravate various disorders. However, ingestion of systemic (oral) zinc supplements tends to activate offsetting mechanisms, and such supplements therefore usually are ineffective. Accordingly, targeted treatments are disclosed herein for suppressing and controlling excessive calprotectin activity, in local tissues. Such methods include targeted injections of zinc solutions, and plasmapheresis treatment. Screening tests also are described for identifying non-protein drugs that can either (i) bind specifically to the zinc-binding sites of calprotectin, or (ii) suppress the release of calprotectin by neutrophil cells.

The invention discloses polyethylene glycol vitamin E succinate and calprotectin modified nanoparticle and a preparation method thereof. The polyethylene glycol vitamin E succinate and calprotectin modified nanoparticle is prepared from the following raw materials in parts by weight: 1 part of active medicine, 20 to 40 parts of phospholipid, 2 to 4 parts of sophorolipid, 1 to 2 parts of calprotectin, and 5 to 10 parts of polyethylene glycol vitamin E succinate. Compared with the prior art, the nanoparticle modified by olyethylene glycol vitamin E succinate, sophorolipid and calprotectin has the advantages that (1) the preparation process is simple and controllable; (2) the stability of the nanoparticle is greatly improved, and the nanoparticle can be stabilized in a solution for up to 6 months; (3) a freeze-drying protective additive is not needed for freezing and drying; the obtained freeze-dried powder dissolved again shows small change on particle size and polydispersity index compared with freeze-dried powder without being dissolved; (4) the targeting for tumor cells is enhanced.

The present invention relates to a method aiding in the assessment of colorectal cancer. The method especially is used in assessing the absence or presence of colorectal cancer in vitro. The method is for example practiced by analyzing biochemical markers, comprising measuring in a stool sample the concentration of the hemoglobin/haptoglobin complex and calprotectin and correlating the concentrations determined to the absence or presence of colorectal cancer. To further improve the assessment of colorectal cancer based on a method of this invention the level of one or more additional marker may be determined together with the hemoglobin/haptoglobin complex and calprotectin in a stool sample and be correlated to the absence or presence of colorectal cancer. The invention also relates to the use of a marker panel comprising the hemoglobin/haptoglobin complex and calprotectin in the early diagnosis of colorectal cancer and it teaches a kit for performing the method of the invention.

The invention discloses a calprotectin combined with lactoferrin antigen test strip and a preparation method thereof, and aims to provide a calprotectin combined with lactoferrin test strip with highdetection speed, simple operation and high sensitivity and also provides a preparation method of the calprotectin combined with lactoferrin test strip with simple process, good repeatability, stable finished structure and good performance. The calprotectin combined with lactoferrin antigen test strip comprises a bottom plate, a sample pad, a marker pad, a test pad and an absorbent pad. The preparation method comprises the steps that firstly the sample pad, the marker pad and the test pad are prepared, and then the sample pad, the marker pad, the test pad and the absorbent pad are in lap jointon the bottom plate in sequence. The calprotectin combined with lactoferrin antigen test strip is applied to the technical field of intestinal inflammatory disease marker protein detection test strips.

The invention provides a kit. The kit comprises the following components of a polymer-containing buffer solution, and a polystyrene latex solution combined with anti-human calprotectin antigen. When the kit is used for detecting calprotectin, the kit has the advantages that in the use process, the kit is only added in two time periods, and the operation is very convenient and rapid; the sensitivity is high, and the low-level calprotectin can be detected; the specificity is strong, the repeatability is good, and the cost is low; the anti-interference ability is strong, and even if the detection sample contains a certain concentration of disruptors, such as hemoglobin, bilirubin, Vc and triglyceride, the influence to the detection result of the kit is little; the kit is suitable for quantitatively detecting the single part and the quick and instantaneous result, and the clinical application value is higher.

The invention discloses a test strip for quantitatively determining calprotectin, a preparation method thereof and a determining method for calprotectin concentration, belonging to the technical field of biotechnology. The test strip comprises a base plate, wherein a sample absorbing pad, a labeled antibody pad, a wrapped film and a water absorbing pad are successively arrayed and attached to the base plate. The test strip provided by the invention has the advantages of accurate test result, convenience and low cost.

The invention relates to a calprotectin detection kit and a detection method. The kit mainly comprises a microwell plate coated with calprotectin antibodies, a calprotectin calibrator, calprotectin antibodies labeled by horseradish peroxidase, an extraction buffer solution, a sample diluent, a substrate solution A (luminol solution), a substrate solution B (hydrogen peroxide solution) and a concentrated washing solution. According to the invention, a double-antibody sandwich immunodetection method is adopted; the microporous plate comprises an immobilized specific antibody; a sample and an enzyme-labeled antibody are added into a reaction hole of an enzyme-labeled plate, and a solid-phase immune complex containing a specific antibody-antigen-enzyme-labeled antibody is formed after a heat preservation reaction; the uncombined enzyme-labeled antibody is removed through washing, and the kit is suitable for large-batch detection; the kit is easy to operate, high in sensitivity, good in specificity, rapid and effective in detection and low in cost and has the application and popularization value.

The invention discloses a calprotectin gene of Meloidogyne graminicola and application of the calprotectin gene, and belongs to the technical field of biology. The calprotectin gene is a calprotectingene MgCRT, disclosed for the first time, of the Meloidogyne graminicola, a nucleotide sequence of the calprotectin gene MgCRT is represented by SEQ ID NO.1, and an amino acid sequence of an expression protein of the calprotectin gene MgCRT is represented by SEQ ID NO.2. Experiments prove that the gene is expressed in subabdominal esophageal glands of the Meloidogyne graminicola, dsRNA of the geneis designed and synthesized, Meloidogyne graminicola larvae are steeped in a dsRNA solution, are washed and are inoculated to rice, and after the gene MgCRT of the Meloidogyne graminicola is silencedby virtue of a method, nematodes invading rice are remarkably decreased, so that the calprotectin gene MgCRT of the Meloidogyne graminicola is relevant with invasion hosts of the Meloidogyne graminicola, and the gene MgCRT can be utilized as a target for preventing and controlling the invasion of the Meloidogyne graminicola on crops by virtue of an RNA interference technique.

The invention relates to a piece of test paper for stool examination. The test paper comprises a base plate, a calprotectin detection part, a lactoferrin detection part, a hemoglobin detection part, atransferring detection part, a vibrio cholera detection part, a pH detection part, and a lactose detection part. A plurality of chambers that are spaced and are not communicated are formed on the base plate. In addition, the invention also relates to a kit for stool examination. The kit includes a stool collection device, a stool transfer device, and a stool extraction buffer solution. The test paper and the kit have advantages of small size, light weight, high portability, and simple usage method. Multiple indicators of a sample can be detected once. The detection speed and sensitivity are high; the price is low. The test paper and the kit can be used in a communication hospital widely, thereby enhancing the capability of preliminary detection of diarrhea in a community hospital.

The present invention relates to a compound for use in a method of diagnosing acute or chronic inflammatory diseases in a subject. In particular, the present invention provides a S100A8/S100A9 heterodimer standard comprising at least one mutation in low- or high-affinity calcium binding hand that can be used in a method of detecting biomarkers of inflammation in a sample. Accordingly, the S100A8/S100A9 heterodimer standard allows for standardizing quantitative immunoassays and quantifying S100A8/S100A9 heterodimers.

The invention relates to a kit for determining calprotectin by latex immunoturbidimetry. The kit comprises a reagent R1 and a reagent R2, wherein the R1 reagent comprises an electrolyte, a stabilizer,a surfactant, a preservative and a buffer solution; the R2 reagent comprises latex particles coated with an anti-human calprotectin polyclonal antibody, an electrolyte, a stabilizer, a surfactant, apreservative and a buffer solution; the average particle size of the latex particles ranges from 50 nm to 500 nm; and the stabilizing agent of the reagent R1 is selected from sorbitol and/or PEG (polyethylene glycol), and the stabilizing agent of the reagent R2 is selected from sorbitol and/or PEG (polyethylene glycol). The kit for determining calprotectin by latex enhanced immunoturbidimetry hashigher stability, and can still maintain higher accuracy under the condition of long-term storage.

The invention provides a calprotectin heterodimer detection kit and application thereof. The kit comprises a coating antibody including an anti-myeloid-associated protein 8/14 antibody.According to the kit disclosed by the invention, the anti-myeloid-associated protein 8/14 antibody is used as a coating antibody and the enrichment effect on the trace amount of calprotectin heterodimer in the sample is realized; and the calprotectin monoclonal antibody is used as the detection antibody to carry out calprotectin detection, so that the interference of other types of calprotectin antigens on the result is basically eliminated and the detection sensitivity and the result accuracy are improved.

The invention discloses a calprotectin monoclonal antibody containing a VHCDR1-3 sequence of a heavy chain variable region and a VLCDR1-3 sequence of a light chain variable region, a preparation method and application thereof in immune detection of inflammatory bowel diseases. When a cutoff value is set as 150microg/g, the sensitivity for diagnosing inflammatory bowel diseases is 72%, and the negative predicted value is 90% or more. On the basis that a mouse monoclonal hybridoma cell strain is successfully obtained, sequencing is conducted, and an effective antibody is obtained, a qualitativeor quantitative detection kit prepared from the recombinant antibody has the advantages of stable performance, accurate quantification and the like, and can realize high-sensitivity and high-specificity rapid detection of calprotectin in a sample.

The invention provides a one-step calprotectin rapid detection kit, comprising a detection kit housing (2), a sampling tube (4), a filter tube (5) and a detection strip (6). The sampling tube (4) canbe inserted into the detection kit housing (2), and the sampling tube (4) is movably connected to the detection kit housing (2). When the sampling tube (4) is inserted into the detection kit housing (2), the sampling tube (4), the filter tube (5) and the detection strip(6) are sequentially in order from the top to the bottom in the detection kit housing(2). The detection process is convenient andfast, and the sample processing can be completed without special operation platform or professional inspection staff.

The invention belongs to the field of biological detection and particularly relates to a joint detection kit for testing intestinal mucosa injury and a preparation method of the joint detection kit. Adetection line T1, a detection T2 and a quality control line are arranged on a detection pad; the detection line T1 is coated with a calprotectin monoclonal antibody; the detection line T2 is coatedwith a hemoglobin monoclonal antibody; the quality control line is coated with goat-anti-mouse or sheep-anti-rabbit IgG; a marking pad is coated with a mixture of the calprotectin monoclonal antibodymarked by a quantum dot and the hemoglobin monoclonal antibody marked by the quantum dot; the quantum dot is a mixture of two different granule particle sizes. The kit provided by the invention is capable of synchronously detecting calprotectin and fecal occult blood in excrement, capable of rapidly and conveniently judging mucosa injury degrees, and is high in detection sensitivity and good in specificity.

The invention provides a calprotectin detection kit and a testing method thereof, and relates to the field of medicine. The kit comprises a shell, a sample pad, a colored particle/fluorescent particlebinding pad, a nitrocellulose membrane and a water absorbing pad are fixed into an inner cavity of the shell, a sample hole is formed in the front side of the shell and located over the sample pad, and an observation window is formed in the front side of the shell and located over the nitrocellulose membrane, a transparent partition plate is arranged in the shell, and divides the inner cavity ofthe shell into two separate spaces which are no communicated. Compared with the prior art, by arranging a dropper and a feeding pipe in the shell, compared with a traditional kit, in the process of making samples dripped into the kit, a user does not need to worry about the sample leakage, and the phenomenon that the samples do not drip into the kit accurately cannot occur.

The invention discloses a calprotectin chemiluminiscence immunoassay kit and a preparation method thereof, belongs to the field of in-vitro detection, and solves the problems of low sensitivity, highcost, poor accuracy, long operation time, low automation degree and incapability of quantification of an existing kit. The chemiluminescence immunoassay kit comprises streptavidin magnetic particles,a chemiluminescence marker labeled calprotectin antibody, a coupling marker labeled calprotectin antibody, a chemiluminescence substrate solution and a calprotectin calibrator, wherein the concentration of the magnetic beads is 0.02-1%, and the particle size is 1.0-3.0 microns, the molar ratio of the calprotectin antibody to the chemiluminiscence marker is 1: (3-20), the molar ratio of the calprotectin antibody to the coupling marker is 1: (5-20), the chemiluminescence marker is acridinium ester, luminol, isoluminol or terpyridyl ruthenium. And the coupling marker is biotin. The method is highin sensitivity, high in accuracy, strong in specificity, high in automatic measurement degree, low in cost, small in error, short in measurement time and wide in application range.

The invention discloses a nondestructive diagnosis and evaluation method for intestinal health conditions of captive moschus berezovskii, and provides an application of a substance for detecting the fecal appearance and fecal occult blood of the moschus berezovskii and the contents of immunoglobulin A, calprotectin and lactoferrin in the feces to the preparation of products for assessing the intestinal health conditions and/or intestinal disease types of the moschus berezovskii. According to the method, the fecal appearance, fecal occult blood and contents of immunoglobulin (such as IgA, lactoferrin and calprotectin) of the moschus berezovskii with healthy feces and abnormal feces are respectively measured, reference constants of physiological indexes such as fecal occult blood and immunoglobulin of feces of the captive moschus berezovskii are explored, and certain basis is provided for the clinic diagnosis of the intestinal health conditions and intestinal inflammation diseases of thecaptive moschus berezovskii.

The invention belongs to the field of immunosensors, and particularly relates to a preparation method and application of a calprotectin biosensor based on graphene. Firstly, a cleaned sensor electrodeis coated with graphene oxide dispersion liquid in a dropwise mode, then the surface of the electrode is coated with a chitosan acetic acid solution in a dropwise mode, graphene oxide is converted into graphene through electrochemical reduction, and calprotectin antibodies are easily enriched and fixed to the surface of the electrode through biocompatibility of the graphene and carboxyl on the surface of the graphene. The electrode is activated, a calprotectin antibody is fixed, an active site is closed, and finally calprotectin is fixed on the electrode through immunoreaction of an antigen and an antibody. As the peak current of the electrode with excellent conductivity of graphene in the electrochemical probe potassium ferricyanide solution is obviously increased, the sensitivity of theimmunosensor can be remarkably improved. The excellent biocompatibility of the graphene can effectively improve the modification amount of the calprotectin antibody on the surface of the electrode, so that the detection range of the electrode on the calprotectin concentration is enlarged.

The invention relates to the field of biological medicine, and especially relates to an application of NY-ESO-1 for enhancing a CA9 immunogenic molecular adjuvant. According to the invention, a poly structure is formed in NY-ESO-1 protein even in a beta-mercaptoethanol loading buffer having normal concentration; a polymerization of NY-ESO-1 is mediated by a disulfide bond between molecules; combination of NY-ESO-1 and unmaturated dendrite cell of human and mice in vitro is related with a self polymerization structure; in vitro combination of NY-ESO-1 and DC cell in marrow is influenced by TLR4; combination of NY-ESO-1 and unmaturated dendrite cell of human and mice can be effected through calprotectin; polymer oligomerization reduces binding capacity of TLR4 and NY-ESO-1; the polymerization structure of NY-ESO-1 and TLR4 in a host participate in an immuno-sphere antibody reaction; and increase of Art v1(wtArt) and CA9 gene immunogenicity depends on NY-ESO-1 gene fusion expression. The NY-ESO-1 has effect for enhancing the CA9 immunogenic molecular adjuvant.